主页 > 医学动态 >
【drug-news】质子泵抑制剂的应用与艰难梭菌相关
BY HEIDI SPLETE 2010-11-05
Elsevier Global Medical News
Breaking News
SAN ANTONIO (EGMN) – Proton pump inhibitor use was associated with an 80% increase in the risk of Clostridium difficile–associated diarrhea, based on data from a meta-analysis of 21 studies.
Proton pump inhibitors (PPIs) are generally considered safe, resulting in some degree of indiscriminate use, said Dr. Sailajah Janarthanan of Wayne State University in Detroit. PPIs have faced scrutiny for a possible association with C. difficile–associated diarrhea (CDAD), but results from previous studies have yielded mixed results, Dr. Janarthanan said.
“Given the millions of individuals on PPIs, even a slight increase in the risk of CDAD conferred by these drugs will have major public health implications,” she emphasized.
To explore the relationship between PPIs and CDAD, Dr. Janarthanan and her colleagues looked at data from 21 peer-reviewed published studies. The 7 cohort studies and 14 case-control studies included 133,054 individuals.
Overall, there was a significant increase in the risk of CDAD in patients taking PPIs (risk estimate, 1.80). The risk estimate in the case-control studies was 1.55 and in the cohort studies 2.07. The CDAD risk was significantly higher for patients taking PPIs whether the types of studies were considered separately or as a whole.
C. difficile represents an escalating threat to public health, and CDAD cost the United States an estimated $3 billion in 2005, Dr. Janarthanan said at the annual meeting of the American College of Gastroenterology.
The results of the studies reviewed by Dr. Janarthanan and her associates were limited by the lack of randomized, controlled trials, she noted, and the impact of PPIs on CDAD remains controversial.
“Indiscriminate use of PPIs without proper indication should be discouraged,” she said. “There is a real-time need for guidelines on the use of PPIs, especially in hospitals.”
Dr. Janarthanan reported having no financial conflicts of interest.
Copyright 2010 Elsevier Global Medical News. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
质子泵抑制剂的应用与艰难梭菌相关腹泻风险增加80%有关
爱思唯尔全球医学资讯
最新进展
圣安东尼奥(EGMN)——美国胃肠病学会年会上报告的一项荟萃分析显示，质子泵抑制剂(PPI)的应用与艰难梭菌相关腹泻(CDAD)风险增加80%有关。
本分析的对象为21项已发表的研究，其中7项为队列研究，14项为病例对照研究，共涉及133,054名受试者。
总体分析发现，PPI服用者的CDAD风险显著增加(风险估计值1.80)。根据研究类型进行单独分析亦发现PPI服用者的CDAD风险显著增加，风险估计值在病例对照研究和队列研究分别为1.55和2.07。
本分析的局限性在于未纳入随机对照研究。
研究者表示，PPI具有良好安全性，这导致其在一定程度上被滥用，因此有必要即时出台PPI临床应用指南。
研究者声明无经济利益冲突。
一项分析指出，质子泵抑制剂的应用与艰难梭菌相关腹泻风险增加80%有关(感谢照片提供者，来自美国CDC的Gilda Jones博士)。
爱思唯尔 版权所有
学科代码:
内科学, 消化病学, 传染病学, 全科医学 【drug-news】FDA发布有关氯吡格雷与奥美拉唑相互作用的安全...发表时间：2010-2-8回帖数：13clopidogrel (marketed as plavix) and omeprazole (marketed as prilosec) - drug interaction [posted 11/17/2009> fda notified healthcare professionals of new safetwww.ruanjian520.com/thread-... - 2010-02-08-快照-【drug-news】FDA发布有关氯吡格雷与奥美拉唑相互作用的安全..." 质子泵抑制剂与肿瘤耐药研究 Studies of proton pump inhibitors ...质子泵抑制剂与肿瘤耐药研究 摘要: 恶性肿瘤对抗癌药物的耐药性是肿瘤患者治疗失败的... 杨胜利,YANG Shengli(江苏大学生命科学学院,镇江,212013;上海交通大学医学院上海市肿...d.wanfangdata.com.cn/...4.aspx-1天前-快照-质子泵抑制剂与肿瘤耐药研究 Studies of proton pump inhibitors ..." 质子泵抑制剂与细胞色素P450的关系-作者:蔡振寨,刘枫,金震东,李...2004年第03期-质子泵抑制剂应用与进展 作者:牛春燕,罗金燕, 期刊 国外医学(消化系疾病... resistance to antitumor drugs 作者:金洁,覃文新,杨胜利, 期刊-核心期刊 生命科学...www.ilib.cn/...05-0465-03.html-2004-05-03-快照-质子泵抑制剂与细胞色素P450的关系-作者:蔡振寨,刘枫,金震东,李..."[标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-27 13:02
医学,生命科学网